Loading organization details...
Loading organization details...
TO STRENGTHEN THE GREATER LYNN COMMUNITY THROUGH RESOURCES AND SERVICES THAT PROVIDE OPPORTUNITIES FOR CHILDREN, FAMILIES AND INDIVIDUALS TO THRIVE.
Source: IRS Form 990 (Tax Year 2024)
Source: IRS e-Filed Form 990 (from the IRS e-File system), Tax Year 2023
Total Revenue
▼$16.9M
Program Spending
88%
of total expenses go to program services
Total Contributions
$16.7M
Total Expenses
▼$13.9M
Total Assets
$24.2M
Total Liabilities
▼$7.4M
Net Assets
$16.8M
Officer Compensation
→$402.3K
Other Salaries
$6M
Investment Income
$199.8K
Fundraising
▼$5,385
Source: USAspending.gov · Searched by organization name
VA/DoD Awards
$95.1M
VA/DoD Award Count
8
Funding from the Department of Veterans Affairs and/or Department of Defense.
Total Federal Funding (partial)
$379.5M
Awards Found
50+
Additional awards may exist. View all on USAspending.gov →
Department of Defense
$32.6M
COLLABORATIVE RESEARCH IN MILITARY CONSEQUENCE MANAGEMENT
Department of Health and Human Services
$25.6M
HEAD START AND EARLY HEAD START
Department of Health and Human Services
$24.8M
HEAD START FULL YEAR/DAY
Department of Health and Human Services
$20.9M
HEAD START & EARLY HEAD START
Department of State
$20.8M
SPECIAL COURT FOR SIERRA LEONE - AMENDMENT 001. THIS IS A COST AMENDMENT TO ADD FUNDS.
Department of Education
$19M
CARES ACT - HIGHER EDUCATION EMERGENCY RELIEF FUND
Department of State
$18M
TO SUPPORT THE "INL/COLOMBIA NATIONAL POLICE SCHOLARSHIP PROGRAM"
Department of Education
$15.7M
CARES ACT - HIGHER EDUCATION EMERGENCY RELIEF FUND
Department of Defense
$15M
COVID-19 DPA3 MEGA-CONSTELLATION CONTROL AND CERTIFICATION OF COMMERCIAL SPACE DATA
Department of Defense
$13.8M
COLLABORATIVE RESEARCH IN HUMAN SCIENCES AND RELATED GENERAL STUDIES AND ANALYSES
Department of Health and Human Services
$13.7M
HEAD START AND EARLY HEAD START
National Aeronautics and Space Administration
$11.7M
THE PROPOSED EFFORT IS SEGREGATED INTO TWO MAIN CATEGORIES: "MURI" AND "CUBESAT." THE MURI EFFORT INCLUDES FLIGHT TEST RADIATION TESTING AND THE PZT LAUNCH LOCK.
Department of Defense
$8.3M
SCALABLE QUANTUM INFORMATION PROCESSING (SQIP) WITH TRAPPED IONS
Department of Defense
$8M
DEFENSE PRODUCTION ACT, TITLE III, AN/SSQ-101B SONOBUOYS PRODUCTION CAPABILITY PROJECT
National Aeronautics and Space Administration
$7.4M
SUPER UNCOOLED MULTI-BAND RADIOMETER SENSOR (SUMRS)
Department of State
$7.1M
TO IMPROVE POLICE COMMUNITY RELATIONS AND ASSIST IN THE CONTROL OF ILLICIT CROPS/
Department of Defense
$7M
COVID-19 DPA3 "LASER DIODE PROCESS OPTIMIZATION PROGRAM"
Department of Health and Human Services
$6.8M
IMPROVING PUBLIC HEALTH GLOBALLY: STRENGTHENING PUBLIC HEALTH IMPACT , SYSTEMS, CAPACITY, AND SECURITY IN SIERRA LEONE
Department of Defense
$6.4M
CERTIFIED TOPOLOGICAL QUANTUM COMPUTATION
Department of Health and Human Services
$5M
INNOVATIVE 3D PRINTED INTRAVAGINAL RING ANELLEO-PRO, THE FIRST SINGLE ADMINISTRATION OF PROGESTERONE FOR INFERTILITY - PROJECT SUMMARY INFERTILITY IS A GLOBAL HEALTH PROBLEM. IN THE US ALONE, ~1.7 MILLION WOMEN ARE TREATED FOR INFERTILITY EVERY YEAR. TO IMPROVE INFERTILITY TREATMENT, THERE IS A STRONG NEED TO PROMOTE PATIENT-FRIENDLY METHODS FOR PROGESTERONE SUPPLEMENTATION IN ASSISTED REPRODUCTIVE TECHNOLOGY (ART). INTRAVAGINAL RINGS, WHICH ARE WELL TOLERATED BY WOMEN, ARE EFFICACIOUS FOR CONTRACEPTION AND HORMONE REPLACEMENT THERAPY, AND HAVE HIGH PATIENT COMPLIANCE, ARE NOW IN DEVELOPMENT FOR ART. HOWEVER, DEVELOPING EFFECTIVE IVRS TO DELIVER PROGESTERONE BEYOND 7 DAYS IS CHALLENGING DUE TO LIMITATIONS OF CURRENT ENGINEERING PROCESSES, AND DIFFICULTY IN CONTROLLING RELEASE RATES, THUS MANDATING DRUG-SPECIFIC CUSTOMIZED IVR DESIGNS. OUR GOAL IS TO ADDRESS THESE LIMITATIONS BY REVOLUTIONIZING THE ENGINEERING AND MANUFACTURING PROCESSES FOR INTRAVAGINAL RINGS, USING A STATE-OF-THE-ART 3D PRINTING PROCESS KNOWN AS CONTINUOUS LIQUID INTERFACE PRODUCTION (CLIP™). USING THE AUTOMATED CLIP PROCESS, WE CAN ENGINEER AND MANUFACTURE IVRS WITH SURFACE GEOMETRIES NOT ACHIEVABLE WITH TRADITIONAL INJECTION MOLDING OR EXTRUSION, WHICH HELP CONTROL DRUG RELEASE. CLIP ENABLES US TO PRECISELY FINE-TUNE DIFFUSION AND RELEASE OF DRUGS, TO ACHIEVE NEAR COMPLETE RELEASE, AND INDEPENDENTLY CONTROL IVR MECHANICAL PROPERTIES. IMPORTANTLY, USING CLIP, WE CAN MANUFACTURE IVRS THAT PROVIDE SUSTAINED RELEASE OF PROGESTERONE TO COVER THE ENTIRE ART TREATMENT PERIOD IN A RAPID AND COST-EFFECTIVE SINGLE-STEP PROCESS. IN THIS PHASE II SBIR PROJECT, WE PROPOSE TO BUILD ON OUR EXISTING DATA FROM PHASE I TO OPTIMIZE A PROGESTERONE IVR NAMED ANELLEO-PRO, TEST ITS EFFICACY IN A RELEVANT MACAQUE MODEL, AND CONDUCT IND-ENABLING STUDIES TO SUPPORT AN IND-APPLICATION. WE WILL IMPLEMENT COMPREHENSIVE RATIONAL IVR DESIGN, USING THE HIGHLY RELEVANT PRECLINICAL SHEEP AND MACAQUE MODELS TO CHARACTERIZE THE SAFETY, PHARMACOKINETIC PROFILES, AND EFFICACY OF OPTIMIZED ANELLEO-PRO. THIS MULTIDISCIPLINARY, CUTTING-EDGE APPROACH WILL DEVELOP A UNIQUE AND HIGHLY INNOVATIVE 3D PRINTED CLIP IVR – ANELLEO-PRO, DELIVERING PROGESTERONE IN A LONG-ACTING, SINGLE ADMINISTRATION TREATMENT OF INFERTILITY.
Department of Defense
$4.1M
SCALABLE MEMORY-ENHANCED ION-TRAP QUANTUM NETWORK (SCINET)
Department of the Treasury
$4M
PURPOSE: THE SOCIAL IMPACT PARTNERSHIPS TO PAY FOR RESULTS ACT (SIPPRA) WAS ENACTED AS TITLE VIII OF DIVISION E OF THE BIPARTISAN BUDGET ACT OF 2018 TO PROVIDE COMPETITIVE GRANTS TO STATE AND LOCAL GOVERNMENTS FOR PROJECTS THAT PRODUCE ONE OR MORE MEASURABLE, CLEARLY DEFINED OUTCOMES THAT RESULT IN SOCIAL BENEFIT AND FEDERAL, STATE OR LOCAL SAVINGS, AND GRANTS TO PAY FOR INDEPENDENT EVALUATORS FOR SUCH PROJECTS. SIPPRA ALSO PROVIDES GRANTS FOR FEASIBILITY STUDIES. ACTIVITIES TO BE PERFORMED: SIPPRA RECIPIENTS WILL RECEIVE PAYMENT UNDER THE PROJECT GRANT IF THEY ACHIEVE ONE OR MORE OUTCOMES SPECIFIED IN THEIR APPROVED PROJECT PLAN, AND SUCH OUTCOMES ARE VALIDATED BY AN INDEPENDENT EVALUATOR. END GOAL/EXPECTED OUTCOMES: SIPPRA IS EXPECTED TO IMPROVE THE LIVES OF FAMILIES AND INDIVIDUALS IN NEED IN THE UNITED STATES BY FUNDING SOCIAL PROGRAMS THAT ACHIEVE REAL RESULTS; DIRECT FUNDS INTO PROGRAMS THAT ACHIEVE DEMONSTRATABLE, MEASURABLE RESULTS; ENSURE FUNDS ARE USED EFFECTIVELY ON SOCIAL SERVICE TO PRODUCE POSITIVE OUTCOME; ESTABLISH THE USE OF SOCIAL IMPACT PARTNERSHIPS TO ADDRESS SOME OF OUR NATION'S MOST PRESSING PROBLEMS; FACILITATE THE CREATION OF PUBLIC-PRIVATE PARTNERSHIPS; AND BRING PAY-FOR-PERFORMANCE TO THE SOCIAL SECTOR. INTENDED BENEFICIARIES: THE RECIPIENTS OF THE SOCIAL SERVICE PROVIDED BY THE AWARDED STATE AND LOCAL GOVERNMENTS. SUBRECIPIENT ACTIVITIES: SUBRECIPIENT ACTIVITIES ARE NOT KNOWN AT THIS TIME. SPECIFIC ACTIVITIES RELATING TO BROADBAND USAGE ARE NOT KNOWN AT THE TIME OF AWARD.
Department of Health and Human Services
$3.6M
ASSESSMENT OF YOUTH INTERVENTIONS IN ASEMBO AND GEM NYANZA, PROVINCE, KENYA
Environmental Protection Agency
$3.5M
DESCRIPTION:THIS AGREEMENT PROVIDES FUNDING TO LEONI TOWNSHIP TO IMPLEMENT ITS WASTEWATER TREATMENT PLANT IMPROVEMENT PROJECT AS DIRECTED IN THE 2022 CONSOLIDATED APPROPRIATIONS ACT OR AS IDENTIFIED IN AN APPROVED TECHNICAL CORRECTION IF ONE HAS BEEN APPROVED FOR THIS PROJECT. ACTIVITIES:THE ACTIVITIES TO BE PERFORMED INCLUDE THE EXECUTION AND IMPLEMENTATION OF A WASTEWATER INFRASTRUCTURE CONSTRUCTION PROJECT. WORKPLAN ACTIVITIES CONSIST OF: IMPROVEMENTS TO INFLUENT HANDLING, BIOSOLIDS STORAGE BARN EXPANSION, UPGRADES TO THE SEPTAGE RECEIVING FACILITY, AND MISCELLANEOUS IMPROVEMENTS. SUBRECIPIENT:NO SUBAWARDS ARE INCLUDED IN THIS ASSISTANCE AGREEMENT.OUTCOMES:THE ANTICIPATED DELIVERABLES INCLUDE NEW FLOW METERS ON THE FIVE MAIN FORCEMAINS THAT DELIVER FLOW TO THE WWTP, EXPANSION OF THE EXISTING BIOSOLIDS STORAGE BARN, UPGRADING THE SCREENING ROOM'S HVAC SYSTEMS, RECONSTRUCTION OF ONSITE ASPHALT ACCESS DRIVES AND RELATED DRAINAGE SYSTEMS. THE EXPECTED OUTCOMES INCLUDE REDUCED INFLOW AND INFILTRATION AND RELIABLE WASTEWATER SERVICE. THE INTENDED BENEFICIARIES INCLUDE RESIDENTS OF JACKSON COUNTY, LENAWEE COUNTY, AND WASHTENAW COUNTY.
Environmental Protection Agency
$3.5M
DESCRIPTION:THE AGREEMENT PROVIDES FUNDING TO LEONARDO ACADEMY. SPECIFICALLY, THE RECIPIENT WILL REPLACE OLDER DIESEL TIER 3 STRADDLE CARRIERS WITH NEWER, CLEANER HYBRID-ELECTRIC STRADDLE CARRIERS TO REDUCE EMISSIONS OF DIESEL PARTICULATE MATTER, NOX AND EXPOSURE TO DIESEL AIR TOXICS IN ESSEX COUNTY, NEW JERSEY. REPLACING OLDER DIESEL CARGO HANDLING EQUIPMENT WITH NEWER HYBRID-ELECTRIC STRADDLE CARRIERS WILL REDUCE EMISSIONS OF DIESEL PARTICULATE MATTER AND OTHER POLLUTANTS SUCH AS NITROGEN OXIDES.ACTIVITIES:LEONARDO ACADEMY WILL ENSURE PROJECT GOALS OF THE SCRAPPING DIESEL STRADDLE CARRIERS AND PURCHASING HYBRID-ELECTRIC STRADDLE CARRIERS ALONG WITH PROJECT PARTNERS. THE ACTIVITIES INCLUDE PURCHASING HYBRID-ELECTRIC CARRIERS THROUGH A COMPETITIVE PROCUREMENT PROCESS AND COORDINATING THE DESTRUCTION AND RECYCLING OF THE OLD ENGINES AND STRADDLE CARRIERS. SUBRECIPIENT:A SUBAWARD WILL BE GIVEN TO THE SUBRECIPIENT, PORT NEWARK CONTAINER TERMINAL. THE ACTIVITIES TO BE IMPLEMENTED THROUGH THE SUBAWARD ENTAIL REPLACING DIESEL-POWERED CARGO HANDLING EQUIPMENT CALLED STRADDLE CARRIERS WITH HYBRID ELECTRIC STRADDLE CARRIERS. THE GRANT WILL BE MANAGED BY LEONARDO ACADEMY WHO WILL OVERSEE THE IMPLEMENTATION OF THE AWARD. THE CARGO HANDLING EQUIPMENT OWNERS, AS SUBRECIPIENTS, WILL PROCURE REPLACEMENT STRADDLE CARRIERS IN COMPLIANCE WITH PROCUREMENT RULES, PERMANENTLY DISABLE AND DECOMMISSION OLD NON-ROAD DIESEL STRADDLE CARRIERS AND SUBMIT ALL REQUIRED DOCUMENTATION TO LEONARDO ACADEMY, WHO WILL THEN SUBMIT THEM TO EPA. PORT NEWARK CONTAINER TERMINALS AND LEONARDO ACADEMY WILL MAKE QUARTERLY AND ANNUAL REPORTS TO EPA TO SUMMARIZE THE STATUS OF THE SCRAPPAGE AND PURCHASE OF THE CARGO HANDLING EQUIPMENT.OUTCOMES:THE ANTICIPATED DELIVERABLES INCLUDE THE REPLACEMENT OF OLD DIESEL CARGO HANDLING EQUIPMENT CALLED STRADDLE CARRIERS WITH NEWER, CLEANER HYBRID-ELECTRIC STRADDLE CARRIERS. THE EXPECTED OUTCOMES INCLUDE REDUCTIONS IN PARTICULATE MATTER AND NITROGEN OXIDES, REDUCING THESE HARMFUL EMISSIONS THROUGHOUT OUR NATION WILL PREVENT PREMATURE DEATHS, ASTHMA RELATED ER VISITS, AIR RELATED HOSPITALIZATIONS, HEART ATTACKS, AND COUNTLESS MISSED WORKDAYS EACH YEAR. THE INTENDED BENEFICIARIES INCLUDE NEAR-PORT COMMUNITIES, PORT DOCKWORKERS AND PORT NEWARK CONTAINER TERMINAL.
Department of Education
$3.3M
HIGHER EDUCATION EMERGENCY RELIEF FUND: INSTITUTIONAL USE
Department of Health and Human Services
$3.1M
NTX-2001, A TRACE AMINE-ASSOCIATED RECEPTOR 1 (TAAR1) PARTIAL AGONIST, FOR THE TREATMENT OF COCAINE USE DISORDER - PROJECT SUMMARY COCAINE USE DISORDER (CUD) IS A MAJOR AND ESCALATING PUBLIC HEALTH CRISIS IN THE UNITED STATES, WITH OVER 1.4 MILLION ADULTS MEETING THE DIAGNOSTIC CRITERIA FOR CUD AND OVERDOSE DEATHS INVOLVING COCAINE INCREASING MORE THAN SIXFOLD BETWEEN 2010 AND 2023. DESPITE DECADES OF RESEARCH, THERE ARE CURRENTLY NO FDA-APPROVED PHARMACOTHERAPIES FOR CUD, AND EXISTING BEHAVIORAL TREATMENTS—SUCH AS CONTINGENCY MANAGEMENT AND COGNITIVE-BEHAVIORAL THERAPY—ARE ONLY MODERATELY EFFECTIVE AND ARE LIMITED BY POOR ADHERENCE. THERE IS AN URGENT NEED FOR A SAFE, EFFECTIVE, AND MECHANISTICALLY TARGETED PHARMACOLOGICAL TREATMENT FOR CUD THAT CAN REDUCE COCAINE USE AND CRAVINGS WITHOUT DISRUPTING NORMAL DOPAMINE FUNCTION IN THE BRAIN. SUCH A THERAPY, IF APPROVED, WOULD NOT ONLY IMPROVE CLINICAL OUTCOMES BUT ALSO REDUCE THE ECONOMIC BURDEN, WHICH WAS LAST ESTIMATED AT $193 BILLION ANNUALLY, AND SOCIETAL COSTS OF UNTREATED STIMULANT USE DISORDERS. THE GOAL OF THE PROPOSED STUDIES IS TO EVALUATE NTX-2001, A NOVEL PARTIAL AGONIST OF TRACE AMINE-ASSOCIATED RECEPTOR 1 (TAAR1), FOR ITS SAFETY, TOLERABILITY, AND EFFICACY IN TREATING CUD. NTX-2001, WHICH IS BEING DEVELOPED BY NEWLEOS THERAPEUTICS, SELECTIVELY MODULATES DOPAMINE RELEASE DURING HIGH-DOPAMINE STATES—SUCH AS THOSE INDUCED BY COCAINE—WITHOUT AFFECTING BASELINE DOPAMINE TONE. PRECLINICAL STUDIES HAVE SHOWN THAT TAAR1 AGONISTS REDUCE COCAINE-SEEKING BEHAVIOR, SELF-ADMINISTRATION, AND REINSTATEMENT. NTX-2001 HAS DEMONSTRATED EFFICACY IN RODENT MODELS AS WELL AS SAFETY AND TOLERABILITY IN EIGHT CLINICAL TRIALS INVOLVING OVER SIX HUNDRED PARTICIPANTS, WITH NO SERIOUS ADVERSE EVENTS OR CLINICALLY SIGNIFICANT ABNORMALITIES. NEUROIMAGING DATA ALSO SUGGEST NTX-2001 MAY REDUCE REWARD-RELATED BRAIN ACTIVITY, SUPPORTING ITS POTENTIAL TO DAMPEN DRUG CUE REACTIVITY. THE PROPOSED STUDIES INCLUDE A PHASE 1 CLINICAL TRIAL TO ASSESS THE SAFETY OF NTX-2001 WHEN CO- ADMINISTERED WITH INTRAVENOUS COCAINE AND A PHASE 2 CLINICAL TRIAL TO EVALUATE ITS POTENTIAL EFFICACY IN REDUCING COCAINE CRAVINGS AND USE. WITH SUCCESSFUL OUTCOMES IN THESE STUDIES, NEWLEOS THERAPEUTICS WILL BE WELL POSITIONED TO RUN REGISTRATIONAL TRIALS AND PURSUE FDA APPROVAL FOR NTX-2001 AS A FIRST-IN-CLASS PHARMACOTHERAPY FOR CUD. THIS WOULD REPRESENT A TRANSFORMATIVE STEP IN ADDICTION TREATMENT AND OPEN THE DOOR TO BROADER APPLICATIONS IN OTHER SUBSTANCE USE DISORDERS.
Department of Health and Human Services
$3M
CATAWBA AND IREDELL: MEDICATION ASSISTED TREATMENT PROGRAM - MCLEOD ADDICTIVE DISEASE CENTER IS APPLYING TO IMPLEMENT THE CATAWBA/IREDELL MEDICATION ASSISTED TREATMENT PROGRAM (CI-MAT) IN TWO WEST/CENTRAL NORTH CAROLINA COUNTIES WITH A POPULATION OF ~354,000, TARGETING THOSE WITH AN OUD AND THE 50% WITH CO-OCCURRING SUBSTANCE USE DISORDERS (SUD). WE WILL FOCUS ON MINORITY AND UNHOUSED CONSUMERS, WITH CLOSE TO TWO-THIRDS ALSO CHALLENGED BY UNTREATED TRAUMA AND BH CHALLENGES. LOCAL MANAGED CARE ORGANIZATION DATA FINDS THAT 2/3’S OF THOSE WITH OUD HAVE TRAUMA HISTORIES OF WHICH ONLY 20% ARE SPECIFICALLY TREATED FOR TRAUMA. THOSE WITH UNTREATED TRAUMA WERE 4X AS LIKELY TO LEAVE TREATMENT WITHIN 4-MONTHS AND HAD 5-7X THE NUMBER OF POSITIVE DRUG SCREENS DURING TREATMENT COMPARED TO THOSE WITHOUT TRAUMA HISTORY. 16% OF THE POPULATION HAS BEEN PRESCRIBED OPIOID MEDICATIONS, MUCH HIGHER THAN THE STATE AVERAGE. INCARCERATION RATES ARE AT OR ABOVE THE STATE AVERAGE AND FOSTER CARE DUE TO OUD AND RELATED ARE 10-25% HIGHER THAN THE STATE AVERAGE. THIS ALSO INDICATES A YOUNGER POPULATION TO BE SERVED. BEHAVIORAL HEALTH AND ADDITIONAL CHALLENGES HAVE SEVERELY LIMITED RETENTION IN MAT PROGRAMS FOR WHICH THIS PROGRAM IS DESIGNED TO IMPROVE. WE WILL SERVE A TOTAL OF 333 CONSUMERS, RANGING FROM 62-70 EACH YEAR. CONSUMERS WILL HAVE THE CHOICE OF AN OPIOID TREATMENT PROGRAM (OTP,) OR AN OFFICE-BASED OPIOID TREATMENT (OBOT), PROGRAM. CONSUMERS WILL RECEIVE APPROPRIATE MEDICATIONS PER THE PROVIDER TYPE WITH EMPHASIS ON REDUCING DIVERSION RISK. SERVICES WILL USE A RANGE OF EVIDENCE-BASED PRACTICES (EBP) FOR TREATMENT NEEDS, RECOVERY-BASED SERVICES FOR OUD AND ANY CO-OCCURRING SUD, A COMPREHENSIVE SCREENING AND ASSESSMENT PROCESS, WITH SERVICES SPECIFIC TO TRAUMA AND BEHAVIORAL HEALTH ISSUES WHEN DETECTED. PEER SUPPORT SERVICES WILL BE AVAILABLE TO ALL CONSUMERS AS WELL AS LINKAGE WITH LOCAL RECOVERY-BASED ORGANIZATIONS TO SUPPORT/MAINTAIN GAINS. WE WILL HAVE SPECIAL EMPHASIS ON THOSE UNHOUSED AND WILL HAVE SOBER HOUSING AVAILABLE AT MULTIPLE LOCATIONS. WE WILL EMPHASIZE RETENTION AND SHARING OF CONSUMERS BETWEEN THE PROGRAMS FOR THE BEST FIT FOR SERVICE. TO SUPPORT THIS, A LOW-THRESHOLD APPROACH WILL BE USED IF REQUESTED AND APPROPRIATE. WE WILL ADDRESS FOUR GOALS: 1) INCREASE USE AND INTEGRATION OF MEDICATION ASSISTED TREATMENT AND EVIDENCE-BASED SERVICES; 2) PROVIDERS WILL USE TRAUMA-INFORMED ASSESSMENTS AND SERVICES AND WILL BE SPECIFICALLY TREATING IDENTIFIED TRAUMA VIA EBP FOR CONSUMERS THAT CONSENT TO TRAUMA TREATMENT; 3) IMPROVE NETWORKING AND AVAILABILITY OF KEY RESOURCES AND POSITIVE SOCIAL ENGAGEMENTS (HOUSING, TRANSPORTATION, SOCIAL CONNECTEDNESS, ENGAGEMENT WITH RECOVERY SERVICES OUTSIDE OF THE TREATMENT CENTER); AND, 4) IMPROVE OUTREACH AND RETENTION EFFORTS TO INCREASE RESOURCES AND COMMON POLICY WITHIN AND BETWEEN PARTICIPATING PROVIDERS IN BOTH COUNTIES. EACH GOAL HAS FROM 3-8 OBJECTIVES THAT WILL FURTHER MEASURE THE GOAL STATEMENTS. TO DEVELOP A SUSTAINABLE MAT PROGRAM, GROUND IT IN DATA/INFORMATION, AND TO MAXIMIZE EFFICIENCY AND IMPACT, WE WILL DOCUMENT THE PROCESS BY COMPLETING AND UPDATING A NEEDS ASSESSMENT, NECESSARY DUE TO SERIOUS FRAGMENTATION AND COMMUNICATION ISSUES THAT IMPEDE OUD/SUD TREATMENT, REFERRALS, AND COMMUNICATION IN THE TARGET COUNTIES AND WIDELY HELD BELIEF SYSTEMS THAT STIGMATIZE OUD AS A NON-DISEASE PROCESS. AN IMPLEMENTATION PLAN TO ENSURE FIDELITY TO THE PROGRAM AND EBPS USED AS WELL AS PROCESSES FOR ALL STATED OBJECTIVES AND PERFORMANCE MEASURES. AN EVALUATION PLAN THAT WILL FOCUS ON DATA MANAGEMENT, PROCESS, FIDELITY, PERFORMANCE MEASURES, GOALS/OBJECTIVES, AND WILL INCLUDE A MIXED METHODS APPROACH. A SUSTAINABILITY PLAN CRITICAL TO MAINTAIN NEW LEVELS OF COMMUNICATION AND RESOURCE SHARING BETWEEN PROVIDERS AS WELL AS IMPROVING COMMUNITY UNDERSTANDING OF OUD AND NETWORKING RESOURCES.
Department of Health and Human Services
$2.9M
TEENAGE PREGNANCY PREVENTION (TIER 1)
Department of Health and Human Services
$2.9M
IMPROVE ACCESS TO BEHAVIORAL AND PHYSICAL HEALTH SERVICES BY TRANSFORMING VALEO BEHAVIORAL HEALTH CARE FROM A COMMUNITY MENTAL HEALTH CENTER TO A CERTIFIED COMMUNITY BEHAVIORAL HEALTH CLINIC - VALEO BEHAVIORAL HEALTH CARE, INC. WILL IMPROVE ACCESS TO BEHAVIORAL AND PHYSICAL HEALTH SERVICES BY TRANSFORMING VALEO FROM A COMMUNITY MENTAL HEALTH CENTER (CMHC) TO A CERTIFIED COMMUNITY BEHAVIORAL HEALTH CLINIC (CCBHC). VALEO'S PRIMARY POPULATION OF FOCUS ARE ADULTS (18+) IN SHAWNEE COUNTY, KANSAS WITH MENTAL HEALTH CONDITIONS, SUBSTANCE USE DISORDERS OR CO-OCCURRING DISORDERS WHO LACK HEALTH INSURANCE COVERAGE, ARE UNDERINSURED, OR CANNOT AFFORD SUBSIDIZED HEALTH INSURANCE, WITH AN EMPHASIS ON INDIVIDUALS WHO ARE 65 AND OLDER, INDIVIDUALS EXPERIENCING HOMELESSNESS, AND THOSE WHO HAVE SERIOUS MENTAL ILLNESS. TOPEKA, THE KANSAS CAPITAL, LIES WITHIN THE BOUNDARIES OF SHAWNEE COUNTY WHICH ENCOMPASSES THE CCBHC SERVICE AREA. SHAWNEE COUNTY IS HOME TO AN ESTIMATED 176,875 RESIDENTS. THERE ARE NO CCBHCS IN THE SERVICE AREA, THOUGH THERE IS ANOTHER CMHC THAT PROVIDES BEHAVIORAL HEALTH SERVICES FOR CHILDREN UP TO 18 YEARS OLD. FOR INDIVIDUALS WITHOUT INSURANCE, VALEO IS ONE OF FOUR PROVIDERS IN THE AREA FOR ADULTS (18+). VALEO IS THE ONLY ADULT PROVIDER WHO WILL PROVIDE SERVICES REGARDLESS OF AN INDIVIDUAL'S ABILITY TO PAY. APPROXIMATELY 17.4% OF THE COUNTY'S POPULATION IS WITHOUT INSURANCE DUE, IN PART, TO KANSAS NOT EXPANDING MEDICAID. THROUGH A SURVEY CONDUCTED BY THE SHAWNEE COUNTY HEALTH DEPARTMENT, RESPONDENTS IDENTIFIED MENTAL HEALTH ISSUES, ALCOHOL/ILLEGAL DRUG ABUSE, PRESCRIPTION DRUG ABUSE/DEPENDENCE, AND OBESITY AS SIGNIFICANT COMMUNITY ISSUES. VALEO WILL SERVE AN ADDITIONAL 2,000 INDIVIDUALS OVER THE COURSE OF THE FOUR-YEAR GRANT PERIOD (500 IN YEAR ONE, 500 IN YEAR TWO, 500 IN YEAR THREE, AND 500 IN YEAR FOUR). THE PROJECT'S FIRST GOAL IS TO INCREASE THE INTEGRATION OF HEALTHCARE SERVICES TO IMPROVE THE OVERALL HEALTH OF THE POPULATION OF FOCUS. OBJECTIVES INCLUDE COLLECTING PRIMARY PROVIDER CARE INFORMATION ON 75% OF CONSUMERS BY THE END OF YEAR ONE AND 100% BY THE END OF YEAR TWO. IN YEAR ONE, 50% OF CONSUMERS WILL RECEIVE PRIMARY CARE SCREENINGS, 75% IN YEAR TWO, 85% IN YEAR THREE, AND 95% IN YEAR FOUR. IN YEAR ONE, 50% OF CONSUMERS WILL RECEIVE CARE COORDINATION, 65% IN YEAR TWO, 75% IN YEAR THREE, AND 95% IN YEAR FOUR. AN ASSERTIVE COMMUNITY TREATMENT (ACT) TEAM WILL BE IMPLEMENTED AND SERVE 25 CONSUMERS IN YEAR ONE, 50 IN YEAR TWO, 75 IN YEAR THREE, AND 100 IN YEAR FOUR. BY YEAR THREE, 50% OF CONSUMERS WITH A BODY MASS INDEX (BMI) OUTSIDE NORMAL PARAMETERS WILL RECEIVE REFERRALS TO APPROPRIATE SUPPORTS, AND 75% WILL RECEIVE REFERRALS BY YEAR FOUR. THE SECOND GOAL IS TO INCREASE TIMELY ACCESS TO SERVICES AND EVIDENCE-BASED PRACTICES TO REDUCE THE NEED FOR MORE RESTRICTIVE LEVELS OF CARE FOR THE POPULATION OF FOCUS. TIME FROM REFERRAL TO SERVICE PROVISION WILL BE DECREASED TO 10 DAYS IN YEAR ONE AND DECREASED TO SEVEN DAYS IN YEAR TWO. SIXTY PERCENT OF CONSUMERS WILL RECEIVE AN EVIDENCE-BASED PRACTICED IN YEAR ONE, 70% IN YEAR TWO, 80% IN YEAR THREE, AND 90% IN YEAR FOUR. VALEO WILL PROVIDE SERVICES TO AN ADDITIONAL 20 INDIVIDUALS 65 YEARS AND OLDER IN YEAR ONE, 40 IN YEAR TWO, 60 IN YEAR THREE, AND 80 IN YEAR FOUR. ACCESS TO SERVICES WILL INCREASE, WITH THE NUMBER OF BILLABLE EVENTS INCREASING BY 10% IN YEAR TWO, 20% IN YEAR THREE, AND 25% IN YEAR FOUR. VALEO WILL ACCOMPLISH THESE OBJECTIVES BY UTILIZING SHORTER-TERM, MORE EFFECTIVE EVIDENCE-BASED PRACTICES, FULLY IMPLEMENTING SAME DAY ACCESS INTAKE, IMPLEMENTING JUST-IN-TIME PSYCHIATRIC PRESCRIBING, UTILIZING A NEW ELECTRONIC HEALTH RECORD WITH A CCBHC MODULE, IMPLEMENTING A FULLY INTEGRATED TREATMENT PLAN, UTILIZING A LEVEL OF CARE INSTRUMENT, ENHANCING AGENCY TRAININGS, EXPANDING THE USE OF SAFETY PLANS, AND IMPROVING ENGAGEMENT OF INDIVIDUALS 65 YEARS AND OLDER.
National Aeronautics and Space Administration
$2.9M
DRS TECHNOLOGIES TAKES PLEASURE IN PRESENTING THIS MULTI-BAND UNCOOLED RADIOMETER IMAGER (MURI) PROPOSAL FOR THE INSTRUMENT INCUBATOR PROGRAM (IIP) THAT WILL PROVIDE IMPROVED RADIOMETRIC IMAGING PERFORMANCE SUBSTANTIALLY REDUCE THE COST COMPLEXITY AND DEVELOPMENT TIME FOR FUTURE POLAR ORBITING EARTH OBSERVATION IMAGING RADIOMETER SENSORS. OUR PROPOSED SOLUTION LEVERAGES CONVENTIONAL LOW COST UNCOOLED MICROBOLOMETERS WITH A COMPACT PIEZO DRIVEN BACKSCAN AND OUR PATENTED TCOMP ALGORITHMS FOR IMPROVED RADIOMETRIC ACCURACY AND STABILITY. OUR SOLUTION ELIMINATES THE NEED FOR CRYOGENIC COOLING SOLVES THE PROBLEM OF IMAGE SMEAR ASSOCIATED WITH THE BOLOMETERS RELATIVELY LONG TIME CONSTANT WHILE SIMULTANEOUSLY ENSURING LOW NEDT. THE OBJECTIVE OF THE DRS PROPOSED MURI PROGRAM IS TO DEMONSTRATE THAT MODERN LOW COST LARGE AREA MICROBOLOMETER FPAS CAN BE UTILIZED TO PROVIDE NARROW BAND RADIOMETRICALLY ACCURATE IMAGING IN 8 LWIR BANDS FOR EARTH SCIENCE APPLICATIONS. THE POTENTIAL EARTH SCIENCE APPLICATIONS FOR THIS TECHNOLOGY ARE LAND SURFACE CLIMATOLOGY MEASUREMENT OF SOIL MOISTURE CONTENT MEASUREMENT OF ECOSYSTEM DYNAMICS VOLCANO MONITORING HAZARD MONITORING GEOLOGY AND SOILS. ON THE IIP PROGRAM DRS PLANS TO DESIGN BUILD TEST AND DEMONSTRATE AN UNCOOLED MICROBOLOMETER BREADBOARD SENSOR HARDWARE FOR EARTH OBSERVATION. OUR SCIENCE PARTNER ROCHESTER INSTITUTE OF TECHNOLOGY (RIT) WILL SUPPORT THE AIRBORNE DATA COLLECTS RADIOMETRIC DATA ANALYSIS AND COMPARISON TO LANDSAT 8 FOR A TRUTH REFERENCE AND THE SCIENCE IMPLEMENTATION ASPECT OF THE INSTRUMENT DATA COLLECTS. DRS/RIT WILL COLLECT AIRBORNE DATA FOR THREE PRIMARY APPLICATIONS IN 8 SPECTRAL BANDS. THE FIRST WILL ASSESS INITIAL DATA QUALITY AND CALIBRATION WITH KNOWN TARGETS DEPLOYED THE SECOND WILL DEMONSTRATE SCIENTIFIC PRODUCTS AVAILABLE OVER VEGETATIVE AND URBAN ENVIRONMENTS WHILE THE THIRD WILL DEMONSTRATE IMPORTANT ASPECTS OF VOLCANO MONITORING. ONE KEY TECHNOLOGICAL SOLUTION IS THE USE OF A PIEZO BACK-SCAN STAGE LOCATED AT THE IMAGE PLANE. THE PIEZO DRIVE VELOCITY WILL BE SET TO MATCH THE AIRCRAFT GROUND VELOCITY DURING IMAGE COLLECTION SUCH THAT THE IMAGE SMEAR FROM THE BOLOMETER S LONG TIME CONSTANT IS ELIMINATED. THIS IS CRITICAL FOR THE USE OF A STANDARD MICROBOLOMETER ARRAY WHICH TYPICALLY HAS ~14MSEC TIME CONSTANT. ANOTHER KEY FEATURE IS THE REAL-TIME RADIOMETRIC CORRECTION THAT WILL OCCUR DURING FLIGHT TO ACCOUNT FOR THE INSTRUMENT AND OPTICS TEMPERATURE CHANGES DURING OPERATION. THIS METHODOLOGY IS BEING UTILIZED BY DRS IN COMMERCIAL RADIOMETERS AND WILL BE IMPLEMENTED HERE TO ACCOUNT FOR INSTRUMENT/OPTICS TEMPERATURE CHANGES AND THEIR CONTRIBUTION TO RADIOMETRIC ERROR. THIS IS A DRAMATIC SHIFT FROM PRIOR RADIOMETERS BUILT FOR EARTH OBSERVATION IN THAT THOSE INSTRUMENTS TYPICALLY COOL THE OPTICS TO REDUCE RADIOMETRIC ERROR. WE ENVISION A SPACE INSTRUMENT USING 10 FPAS WITH UP TO 12 SPECTRAL FILTERS TO COVER A GROUND SWATH WIDTH OF 310KM FROM A 705KM ALTITUDE ORBIT AND A 100M GSD. FOR THIS AIRBORNE DEMO WE PLAN TO UTILIZE 4 FPAS WITH 8 SPECTRAL BAND FILTERS TO DEMONSTRATE THE KEY TECHNOLOGY WITHIN THE MORE LIMITED IIP PROGRAM BUDGET. FOR AN AIRBORNE DEMO USING 120MM EFL F/1 OPTICS AT 15 000FT ALTITUDE WILL HAVE A 0.65M GSD WITH TWO PARALLEL SWATH WIDTHS OF 414KM SEPARATED BY A GAP OF 619M. WE WILL SHOW DIRECT APPLICABILITY TO A SPACE INSTRUMENT AND HOW IT IS EASILY SCALABLE USING A STAGGER BUTTED ARRAY APPROACH. MUCH OF THE SAME HARDWARE COULD BE UTILIZED ON A SPACE VERSION OF THIS INSTRUMENT. PERIOD OF PERFORMANCE OF THIS IIP PROJECT IS EXPECTED TO BE 36 MONTHS. THE FIRST YEAR OF THE PROGRAM WILL INVOLVE THE DESIGN OF THE INSTRUMENT HARDWARE THE SECOND YEAR WILL BE THE BUILD OF THE COMPONENTS INTEGRATION AND ASSEMBLY OF THE INSTRUMENT AND THE THIRD YEAR WILL BE LABORATORY TEST OF THE INSTRUMENT AND AIRBORNE FIELD TESTING. ENTRY LEVEL TRL FOR THIS INSTRUMENT IS 3; EXIT LEVEL TRL AT THE END OF YEAR 3 WILL BE 6.
Department of Health and Human Services
$2.7M
EVALUATION OF A DUAL PPAR AGONIST FOR TREATMENT OF ALZHEIMER'S DISEASE - SUMMARY ALZHEIMER’S DISEASE (AD) IS THE SIXTH LEADING CAUSE OF DEATH IN UNITED STATES, AFFECTING 5M PEOPLE, YET THIS INDICATION LACKS EFFECTIVE THERAPEUTICS. THE LEAD CO-INVESTIGATOR AT THE ACADEMIC PERFORMANCE SITE HAS DEVELOPED A NOVEL DUAL PEROXISOMAL PROLIFERATOR ACTIVATING RECEPTOR DELTA/GAMMA (PPARD/) AGONIST CALLED OL-003 (PREVIOUSLY AU9). THE PHASE I SBIR PROJECT DEMONSTRATED THAT OL-003 REDUCED AD-RELATED PATHOLOGIES, INCLUDING AMYLOID ACCUMULATION, TAU PHOSPHORYLATION AND NEUROINFLAMMATION, AND IMPROVED INSULIN SIGNALING, NEURONAL PLASTICITY AND BEHAVIORAL DEFICITS, WHILE EXHIBITING NO HEART OR LIVER TOXICITY IN 3XTG-AD MICE. THE COMPANY IS A PRIVATE PRECLINICAL BIOTECHNOLOGY COMPANY DEVELOPING NOVEL THERAPIES FOR MITIGATING AD. THE COMPANY HAS IN-LICENSED THE PATENT FOR OL-003 FROM OUR ACADEMIC PARTNER. STUDIES OUTLINED IN THIS PHASE II APPLICATION ARE DESIGNED TO TEST EFFICACY IN TWO ADDITIONAL ANIMAL MODELS AND ASSESS PHARMACOLOGY AND TOXICOLOGY IN GLP AND NON-GLP STUDIES. IF SUCCESSFUL, THIS INFORMATION WILL POSITION OL-003 FOR ADDITIONAL IND-ENABLING STUDIES (CMC IN PARTICULAR) TO SUBMIT AN IND APPLICATION AND BEGIN FIRST-IN- HUMAN CLINICAL TRIALS. THREE AIMS ARE PROPOSED. IN AIM 1, RESEARCH WILL BE PERFORMED USING THE TE4 MOUSE MODEL TO TEST THE EFFECTIVENESS OF OL-003 AGAINST TAU-DRIVEN NEUROPATHOLOGY IN THE CONTEXT OF APOE4, THE STRONGEST GENETIC RISK FACTOR FOR LATE-ONSET AD. STUDIES WILL INCLUDE MEASURING THE IMPACT OF OL-003 ON PHOSPHORYLATED TAU LEVELS, GLIOSIS AND NEURODEGENERATION. IN AIM 2, THE IMPACT OF OL-003 ON GLUCOSE UTILIZATION, MITOCHONDRIAL FUNCTION AND NEUROMETABOLISM IN THE BRAINS OF MICE WILL BE STUDIED. CURRENT RESEARCH SUPPORTS THE HYPOTHESIS THAT AD PROGRESSION IS DRIVEN BY ENERGY DYSREGULATION, MITOCHONDRIAL DEFECTS, AND BRAIN INSULIN RESISTANCE AND THE 5XFAD MODEL IS SUITABLE FOR THESE STUDIES. IN AIM 3, RESEARCH PERFORMED UNDER GLP CONDITIONS WILL DETERMINE IF OL-003 IS SAFE IN ACUTE AND 6-MONTH REPEAT DOSE TOXICITY STUDIES AS WELL AS GENOTOXICITY AND CARCINOGENICITY STUDIES. TOXICOKINETIC ANALYSIS AS WELL AS NEUROLOGIC, CARDIOVASCULAR, AND PULMONARY PARAMETERS WILL BE EVALUATED. ADDITIONAL IN VITRO STUDIES WILL ADDRESS DRUG-DRUG INTERACTION POTENTIAL, INCLUDING EFFECTS ON DRUG TRANSPORTER ACTIVITY AND EXPRESSION, AS WELL AS TARGET SELECTIVITY ASSAYS AGAINST OFF-TARGET NUCLEAR RECEPTORS AND METABOLITE IDENTIFICATION. UPON SUCCESSFUL COMPLETION OF THIS PROJECT, THE COMPANY WILL POSSESS A DATA PACKAGE OF IND-ENABLING RESEARCH THAT SHOULD BE ATTRACTIVE FOR A LICENSE DEAL OR PARTNERSHIP WITH A PHARMACEUTICAL COMPANY.
Department of Education
$2.5M
FUNDS BE USED TO COVER EXPENSES RELATED TO THE DISRUPTION OF CAMPUS OPERATIONS DUE TO CORONAVIRUS INCLUDING ELIGIBLE EXPENSES UNDER A STUDENT’S COST OF ATTENDANCE, SUCH AS FOOD, HOUSING, COURSE MATTER
Department of Education
$2.4M
OLIKO A LAU KA IKE, KNOWLEDGE BUDDING FORTH AND MULTIPLYING
Department of Health and Human Services
$2.2M
PHASE 3 TRIAL OF PP-01 FOR MITIGATION OF CANNABIS WITHDRAWAL IN CUD - PROJECT SUMMARY CANNABIS USE DISORDER (CUD) AFFECTS AN ESTIMATED 20.6 MILLION INDIVIDUALS IN THE UNITED STATES AND REMAINS A GROWING PUBLIC HEALTH CONCERN AS CANNABIS USE INCREASES ACROSS ALL AGE GROUPS. DESPITE THIS, THERE ARE CURRENTLY NO FDA-APPROVED MEDICATIONS TO TREAT CUD OR TO ALLEVIATE CANNABIS WITHDRAWAL SYNDROME (CWS) WHICH IS A PRIMARY DRIVER OF RELAPSE AND CONTINUED CANNABIS USE. INDIVIDUALS WITH CUD WHO ATTEMPT TO STOP OR REDUCE CANNABIS FREQUENTLY EXPERIENCE DISTRESSING AND OFTEN SEVERE WITHDRAWAL SYMPTOMS—INCLUDING ANXIETY, IRRITABILITY, SLEEP DISTURBANCES, WEIGHT LOSS, RESTLESSNESS, CRAVINGS, AND PHYSICAL SYMPTOMS—THAT UNDERMINE THE EFFECTIVENESS OF BEHAVIORAL THERAPIES LEADING TO POOR ADHERENCE AND HIGH DROPOUT RATES. THE LACK OF EFFECTIVE PHARMACOLOGICAL INTERVENTIONS FOR CWS REPRESENTS A CRITICAL AND URGENT UNMET MEDICAL NEED. PLEOPHARMA IS DEVELOPING PP-01, A NOVEL MEDICATION-ASSISTED THERAPY THAT UTILIZES A PARTIAL CB1 AGONIST COMBINED WITH A GABAERGIC AGENT IN A UNIQUE REVERSE TAPER-TITRATION REGIMEN. THIS APPROACH IS DESIGNED TO MITIGATE WITHDRAWAL BY TARGETING UNDERLYING DERANGEMENTS IN THE ENDOCANNABINOID AND DOPAMINERGIC REWARD SYSTEMS. DATA PRESENTED AT THE 2024 AMERICAN ACADEMY OF ADDICTION PSYCHIATRY (AAAP) ANNUAL MEETING DEMONSTRATED THAT PP-01 SIGNIFICANTLY REDUCED WITHDRAWAL SYMPTOMS COMPARED TO PLACEBO (P < 0.0001), AS MEASURED BY THE CANNABIS WITHDRAWAL SCALE, WITH AN EFFECT SIZE OF 78% DURING THE PEAK WITHDRAWAL PERIOD OVER DAYS 2–5. THE STUDY ALSO SHOWED STATISTICALLY SIGNIFICANT AND MEANINGFUL IMPROVEMENTS IN SLEEP, CRAVINGS, APPETITE, AND EVENING CORTISOL LEVELS. DATA FROM A PHASE 2B RANDOMIZED, DOUBLE-BLIND, ACTIVE AND PLACEBO-CONTROLLED CLINICAL TRIAL RECENTLY PRESENTED AT THE 2025 COLLEGE ON PROBLEMS OF DRUG DEPENDENCE (CPDD) ANNUAL MEETING ALSO DEMONSTRATED A STATISTICALLY SIGNIFICANT REDUCTION IN WITHDRAWAL SYMPTOMS ALONG WITH A DECREASE IN CANNABIS USE WITH MORE ABSTINENCE DAYS. PP-01 WAS SAFE AND WELL-TOLERATED. BASED ON THESE FINDINGS AND GIVEN THE SERIOUSNESS AND UNMET NEED, THE FDA GRANTED FAST TRACK DESIGNATION TO PP-01, AND AN END-OF-PHASE 2 MEETING CONFIRMED REGULATORY ALIGNMENT ON THE PROPOSED PHASE 3 TRIAL DESIGN, ENDPOINTS, AND DEVELOPMENT PATHWAY. THIS APPLICATION PROPOSES A MULTISITE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND LONG-TERM IMPACT OF PP-01 IN ADULTS WITH CUD AND A HISTORY OF CANNABIS WITHDRAWAL. THE CO-PRIMARY ENDPOINTS WILL ASSESS REDUCTION IN WITHDRAWAL SEVERITY DURING A 34 DAY TREATMENT PERIOD. SECONDARY AND EXPLORATORY OUTCOMES INCLUDE SLEEP, CRAVING, MOOD, ABSTINENCE RATES, AND OTHER FUNCTIONAL MEASURES. THE TRIAL WILL BE CONDUCTED AT CLINICAL SITES WITH A PROVEN TRACK RECORD OF RECRUITING AND RETAINING PARTICIPANTS WITH SUBSTANCE USE DISORDERS AND WILL BE SUPPORTED BY AN EXPERIENCED CONTRACT RESEARCH ORGANIZATION (CRO). THIS PIVOTAL STUDY IS DESIGNED TO GENERATE THE DATA REQUIRED FOR A NEW DRUG APPLICATION (NDA). IF SUCCESSFUL, THIS PROJECT WILL LEAD TO THE FIRST FDA-APPROVED TREATMENT FOR CWS IN PATIENTS WITH CUD AND OFFER A NEW THERAPEUTIC OPTION FOR MILLIONS OF AMERICANS STRUGGLING WITH CANNABIS ADDICTION.
Department of Commerce
$2.2M
THIS INVESTMENT AMENDMENT WILL PROVIDE SUFFICIENT ADDITIONAL FUNDS TO CONSTRUCT A 40,000 SQUARE-FOOT, HIGH-TECH BUSINESS INCUBATOR WITHIN INNOVATION PARK OF TALLAHASSEE. THE LEON COUNTY RESEARCH AND DEVELOPMENT AUTHORITY OVERSEES THE PARK AND WORKS WITH FLORIDA STATE UNIVERSITY, FLORIDA A&M UNIVERSITY AND TALLAHASSEE COMMUNITY COLLEGE, AMONG OTHER PUBLIC AND PRIVATE SECTOR ENTITIES. THE INCUBATOR, WILL AID IN THE FORMATION AND EXPANSION OF TECHNOLOGY BUSINESSES, DISSEMINATING TECHNOLOGIES TO EXISTING BUSINESSES, AND ESTABLISHING NEW BUSINESS OPERATIONS THROUGHOUT THE REGION. IT WILL SUPPORT LONG-TERM ECONOMIC RECOVERY IN THE AFTERMATH OF HURRICANE MICHAEL AND IS FUNDED UNDER EDA'S FY19 DISASTER SUPPLEMENTAL PROGRAM. THIS PROJECT WAS MADE POSSIBLE BY THE REGIONAL PLANNING EFFORTS LED BY THE APALACHEE REGIONAL PLANNING COUNCIL. EDA FUNDS APALACHEE REGIONAL PLANNING COUNCIL TO BRING TOGETHER THE PUBLIC AND PRIVATE SECTORS TO CREATE AN ECONOMIC DEVELOPMENT ROADMAP TO STRENGTHEN THE REGIONAL ECONOMY, SUPPORT PRIVATE CAPITAL INVESTMENT AND CREATE JOBS.
Department of Housing and Urban Development
$2M
PURPOSE: CONGRESS ANNUALLY APPROPRIATES FUNDS FOR THE CAPITAL FUND, INCLUDING THE EMERGENCY AND NON-PRESIDENTIALLY DECLARED NATURAL DISASTER SET-ASIDE. THE ANNUAL APPROPRIATIONS ACTS ALSO PERMITS HUD TO USE A PORTION OF THE EMERGENCY AND NON-PRESIDENTIALLY DECLARED NATURAL DISASTER SET-ASIDE FOR SAFETY AND SECURITY FUNDING. HUD AWARDS EMERGENCY AND NON-PRESIDENTIALLY DECLARED NATURAL DISASTER GRANTS TO COVER CAPITAL NEEDS ARISING FROM EMERGENCIES AND NON-PRESIDENTIALLY DECLARED NATURAL DISASTERS OCCURRING IN THE SAME FEDERAL FISCAL YEAR (FFY). FOR EXAMPLE, PUBLIC HOUSING AGENCIES (PHAS) WITH CAPITAL NEEDS ARISING FROM A NON-PRESIDENTIALLY DECLARED NATURAL DISASTER IN FFY 2023 MAY ONLY RECEIVE FUNDS FROM THE FFY 2023 EMERGENCY AND NON-PRESIDENTIALLY DECLARED NATURAL DISASTER SET-ASIDE. APPROXIMATELY 2,770 PHAS SERVING NEARLY ONE MILLION UNITS, IN ALL 50 STATES AND TERRITORIES ARE ELIGIBLE TO APPLY. GRANTS ARE AWARDED ON A FIRST-COME, FIRST-SERVED BASIS UNTIL THE EMERGENCY AND NON-PRESIDENTIALLY DECLARED NATURAL DISASTER SET-ASIDE FUNDS ARE EXHAUSTED. INSURANCE COVERAGE, WHICH IS REQUIRED BY THE ANNUAL CONTRIBUTIONS CONTRACT (ACC), SHOULD BE A PHA’S PRIMARY SOURCE OF FUNDING FOR REPAIR OR REPLACEMENT COSTS ASSOCIATED WITH EMERGENCIES AND NON-PRESIDENTIALLY DECLARED NATURAL DISASTERS. PHAS ARE ELIGIBLE FOR PERMANENT RECONSTRUCTION ASSISTANCE THROUGH THE FEDERAL EMERGENCY MANAGEMENT AGENCY (FEMA) FOR PRESIDENTIALLY-DECLARED NATURAL DISASTERS. FEMA MAY ALSO PROVIDE EMERGENCY ASSISTANCE DURING NON-PRESIDENTIALLY DECLARED NATURAL DISASTERS FOR CERTAIN ACTIVITIES SUCH AS DEBRIS REMOVAL, DEMOLITION OF UNSAFE STRUCTURES, AND ANY ACTIONS NECESSARY TO REDUCE AN IMMEDIATE THREAT TO LIFE, PROPERTY, AND PUBLIC HEALTH AND SAFETY. ADDITIONAL INFORMATION ON THE PUBLIC HOUSING CAPITAL FUND IS LOCATED ON THE OFFICE OF CAPITAL IMPROVEMENTS WEBSITE: HTTPS://WWW.HUD.GOV/PROGRAM_OFFICES/PUBLIC_INDIAN_HOUSING/PROGRAMS/PH/CAPFUND ADDITIONAL INFORMATION ON PUBLIC HOUSING FUNDING CAN BE FOUND BY ACCESSING HTTPS://WWW.HUD.GOV/PROGRAM_OFFICES/PUBLIC_INDIAN_HOUSING/PROGRAMS/PH AND REVIEWING THE PUBLIC HOUSING DASHBOARD LINKED UNDER THE “DATA DASHBOARD AND ANALYTICS”.; ACTIVITIES TO BE PERFORMED: THE DEFINITIONS OF “EMERGENCY” AND “NON-PRESIDENTIALLY DECLARED NATURAL DISASTER” ARE USED IN DETERMINING ELIGIBILITY FOR EMERGENCY AND NON-PRESIDENTIALLY DECLARED NATURAL DISASTER GRANTS: • EMERGENCY: AN UNFORESEEN OR UNPREVENTABLE EVENT OR OCCURRENCE THAT POSES AN IMMEDIATE THREAT TO THE HEALTH AND SAFETY OF THE RESIDENTS (INCLUDING FIRE SAFETY) THAT MUST BE CORRECTED WITHIN ONE YEAR OF FUNDING. EXAMPLES OF EMERGENCIES ARE BOILER FAILURE, WATER INTRUSION CAUSING MOLD GROWTH, SEWER LINE FAILURE, AND SEVERE ELECTRICAL PROBLEMS. A PHA MUST BE ABLE TO DEMONSTRATE THAT IT HAS PROPERLY MAINTAINED STRUCTURES AND EQUIPMENT. • NON-PRESIDENTIALLY DECLARED NATURAL DISASTER: AN EXTRAORDINARY EVENT, SUCH AS AN EARTHQUAKE, FLOOD, OR HURRICANE, AFFECTING A PUBLIC HOUSING PROPERTY OWNED AND MANAGED BY A PHA, BUT EXCLUDING AREAS COVERED BY A PRESIDENTIALLY-DECLARED EMERGENCIES AND MAJOR DISASTERS UNDER THE ROBERT T. STAFFORD DISASTER RELIEF AND EMERGENCY ASSISTANCE ACT, AS THOSE AREAS ARE ELIGIBLE FOR FUNDING FROM THE FEDERAL MANAGEMENT AGENCY (FEMA). CAPITAL FUND DISASTER FUNDING CAN ONLY BE USED FOR ACTIVITIES AND COSTS ASSOCIATED WITH THE REPAIR OR REPLACEMENT OF A PUBLIC HOUSING PROJECT ONLY IF THE PUBLIC HOUSING PROJECT WAS DAMAGED BECAUSE OF AN EMERGENCY OR NON-PRESIDENTIALLY DECLARED NATURAL DISASTER. ACTIVITIES TO BE PERFORMED ARE TO PROVIDE EMERGENCY SAFETY MEASURES FOR PUBLIC HOUSING RESIDENTS THAT CAN INCLUDE RELOCATION AND THE COST TO PROVIDE TEMPORARY HOUSING TO PUBLIC HOUSING RESIDENTS UNTIL PUBLIC HOUSING UNITS CAN BE REPAIRED AND CAN BE COVERED BY THE EMERGENCY AND NON-PRESIDENTIALLY DECLARED NATURAL DISASTER GRANT (SUCH AS HOTEL, MOVING VAN RENTAL, TEMPORARY STORAGE, BOXES.). ACTIVITIES TO BE PERFORMED ARE CONTAINED WITHIN THE GRANTEE’S APPROVED GRANT APPLICATION. EXAMPLES OF TYPICAL EMERGENCY SITUATIONS CAN INCLUDE BUT NOT LIMITED TO ELEVATOR FAILURES IN ELDERLY BUILDINGS, WATER PIPE BURST AND FLOODING SITUATIONS, SEWAGE BACKUP AND INTRUSIONS, SEISMIC ACTIVITY DAMAGE, TREE ROOT INTRUSION, FAILED HVAC SYSTEM, AND BOILER LOSS DURING COLD WEATHER. ; EXPECTED OUTCOMES: THE EXPECTED OUTCOMES FOR PUBLIC HOUSING EMERGENCY/DISASTER CAPITAL FUNDS ARE THE IMMEDIATE SAFETY MEASURES FOR PUBLIC HOUSING RESIDENTS AND THE REMEDIATION OF THE SPECIFIC APPROVED EMERGENCY/DISASTER PROJECT. THE MEASURABLE OUTCOME OF THIS GRANT IS THAT HUD WILL BE ABLE TO TRACK THE AMOUNT OF DOLLARS SPENT ON EMERGENCY AND DISASTER ELIGIBLE ACTIVITIES BASED ON THE APPROVED GRANT APPLICATION. ; INTENDED BENEFICIARIES: THE INTENDED BENEFICIARIES FOR PUBLIC HOUSING EMERGENCY/DISASTER CAPITAL FUNDS ARE LOW-INCOME PUBLIC HOUSING RESIDENTS.; SUBRECIPIENT ACTIVITIES: THE RECIPIENT DOES NOT INTEND TO SUBAWARD FUNDS.
Department of Health and Human Services
$2M
NOVEL AND FUNCTIONALLY SELECTIVE 5-HT2C RECEPTOR AGONIST FOR TREATING ALCOHOL USE DISORDER - PROJECT SUMMARY THE GOAL OF THIS PROJECT IS TO CONFIRM AND EXTEND THE DRUG CANDIDACY OF KB128 AS A NOVEL THERAPEUTIC MEDICATION FOR ALCOHOL USE DISORDER (AUD), A COMMON AND DEVASTATING ILLNESS WITH INADEQUATE TREATMENT OPTIONS. CURRENT DRUGS APPROVED BY THE FDA FOR AUD ARE CHARACTERIZED BY LOW EFFICACY AND STEREOTYPICAL SIDE EFFECTS THAT REDUCE TREATMENT ADHERENCE. THE 5-HT2C RECEPTOR IS A VALIDATED THERAPEUTIC DRUG TARGET FOR AUD. HOWEVER, PREVIOUS ATTEMPTS TO DESIGN SELECTIVE 5-HT2C RECEPTOR LIGANDS HAVE BEEN PLAGUED BY UNDESIRABLE OFF-TARGET EFFECTS, INCLUD- ING ABERRANT ACTIVATION OF 5-HT2A (HALLUCINATIONS) AND 5-HT2B (VALVULOPATHY), OR A LACK FUNCTIONAL SELECTIVITY BY ACTIVATING BOTH GQ SIGNALING (MEDIATING THE PUTATIVE THERAPEUTIC EFFECT) AND Β-ARRESTIN SIGNALING (LEADING TO RECEP- TOR INTERNALIZATION AND ATTENUATION OF SIGNAL). PRODUCTION AND COMMERCIALIZATION OF A SAFE AND SELECTIVE 5-HT2C RECEPTOR AGONIST WITH FUNCTIONAL GQ BIAS, NEGLIGIBLE Β-ARRESTIN RECRUITMENT, AND NO HALLUCINOGENIC OR CARDIOTOXIC LIABILITIES ASSOCIATED WITH 5-HT2A AND 5-HT2B RECEPTOR ACTIVATION WOULD BE A MARKET-CHANGING DIFFERENTIATOR; NO 5- HT2C AGONIST COMMERCIALIZED THUS FAR EXHIBITS THIS PROFILE. KÜLEON, LLC HAS DEVELOPED A PROPRIETARY PLATFORM OF MOLECULAR SCAFFOLDS WITH UNIQUE RECEPTOR DOCKING PROFILES. OUR PRELIMINARY STUDIES DEMONSTRATE LEAD CANDIDATE KB128 EXHIBITS HIGH SELECTIVITY FOR 5-HT2C, GQ-MEDIATED SIGNALING BIAS WITH MINIMAL Β-ARRESTIN RECRUITMENT, FAVOR- ABLE METABOLIC PROFILE, NO HALLUCINOGENIC OR CARDIOTOXIC LIABILITIES, AND EFFICACY IN A PILOT AUD STUDY IN RODENTS. OUR PHASE I OBJECTIVE FOR KB128 IS TO DEMONSTRATE PRECLINICAL EFFICACY IN MORE EXTENSIVE AUD BEHAVIORAL MODELS, FAVORABLE PHARMACOKINETICS, AND NO OFF-TARGET TOXICITY. WE WILL ACCOMPLISH THIS IN THE FOLLOWING TWO AIMS. (1) DEMONSTRATE KB128’S ABILITY TO ATTENUATE ALCOHOL SELF-ADMINISTRATION AND STRESS-INDUCED RELAPSE IN VALIDATED RO- DENT MODELS. 5-HT2C RECEPTOR SIGNALING HAS BEEN IMPLICATED IN THE DEVELOPMENT AND MAINTENANCE OF AUD, AND PRIOR STUDIES HAVE SHOWN THAT 5-HT2C RECEPTOR AGONISTS CAN SIGNIFICANTLY DECREASE ALCOHOL CONSUMPTION IN BOTH RODENTS AND HUMANS. STRESS-INDUCED RELAPSE AS A SECONDARY READOUT OF A SELF-ADMINISTRATION STUDY CAN PROVIDE AN INVALUABLE MODEL FOR TESTING A DRUG’S ABILITY TO ATTENUATE STRESS-INDUCED REINSTATEMENT OF ALCOHOL-SEEKING BE- HAVIOR IN BOTH MALE AND FEMALE RODENTS. (2) DEMONSTRATE FAVORABLE PHARMACOKINETICS AND A LACK OF CARDIOTOXICITY AND DRUG-DRUG INTERACTIONS (DDIS) FOR KB128. KB128 WILL BE TESTED IN A VARIETY OF ADMET STUDIES IN AT LEAST 5 SPECIES, INCLUDING PLASMA STABILITY AND PLASMA PROTEIN BINDING FOR ALL SPECIES TESTED. AN IN VITRO CARDIOMYOCYTE ASSAY WILL BE CONDUCTED TO MEASURE CHANGES IN INTRACELLULAR CA++ TRANSIENTS; SUCCESS WILL BE DEFINED BY <15% CHANGE IN MEAN PEAK RATE, PEAK SPACING, AND CALCIUM TRANSIENT DURATION. CYP450 INDUCTION, CYP450 REACTION PHENOTYPING AND CYP450 TIME-DEPENDENT AND DIRECT/REVERSIBLE INHIBITION ASSAYS WILL BE CONDUCTED TO CONFIRM THAT KB128 DOES NOT EXHIBIT POTENTIAL CYTOTOXICITY AND NEGATIVE DDIS. OUR RESEARCH TEAM COMBINES EXPERTISE IN SMALL MOLECULE DRUG DEVELOPMENT, IN VIVO PHARMACOLOGY, PRECLINICAL BIOLOGICAL TESTING IN RODENT AUD MODELS, PATENT PROCUREMENT, AND COMMERCIALIZATION.
National Science Foundation
$1.8M
ENHANCED EARTH SYSTEM TEACHING THROUGH REAL EARTH INQUIRY
Department of Health and Human Services
$1.8M
PROJECT TITLE NOT PROVIDED
Department of Health and Human Services
$1.7M
PROTECTING AND IMPROVING PUBLIC HEALTH GLOBALLY: BUILDING AND STRENGTHENING PUBLIC HEALTH IMPACT, SYSTEMS, CAPACITY, AND SECURITY IN SIERRA LEONE
Department of Health and Human Services
$1.7M
DEVELOPMENT OF A COLORIMETRIC SENSOR FOR DETECTION OF CEREBROSPINAL FLUID LEAKS - PROJECT SUMMARY CHEMELEON, INC. IS A NYC-BASED STARTUP THAT IS DEVELOPING A NOVEL COLORIMETRIC BIOSENSOR THAT RAPIDLY DIAGNOSES CEREBROSPINAL FLUID (CSF) LEAKS AT THE POINT-OF-CARE (POC), SUCH AS BY DOCTORS TO DIAGNOSE TRAUMATIC BRAIN INJURY (TBI) PATIENTS IN THE EMERGENCY DEPARTMENT (ED), OR THE EMERGENCY MEDICAL TECHNICIAN (EMT) IN THE AMBULANCE, OR DURING INTRAOPERATIVE AND POST-OPERATIVE CARE FOR SPINAL AND OTOLARYNGOLOGICAL SURGERIES. CSF LEAKS OCCUR WHEN THE FLUID THAT CUSHIONS THE BRAIN AND SPINE ESCAPES THROUGH RUPTURES IN THE SURROUNDING MEMBRANES. THESE LEAKS ARE LARGELY CAUSED BY TBIS BUT ARE ALSO A RISK DURING SPINAL SURGERIES, OTOLARYNGOLOGICAL SURGERIES, LUMBAR PUNCTURES AND EPIDURALS AND THEY CAN ALSO BE SPONTANEOUS. DISTINGUISHING CSF LEAKS FROM OTHER BODILY FLUIDS IS A WELL-KNOWN PROBLEM FOR ED DOCTORS, EMTS AND SURGEONS AS THE LEAKS OFTEN PRESENT AS UNILATERAL RHINORRHEA OR OTORRHEA, A CLEAR WATERY DISCHARGE FROM THE NOSE OR EAR, OR AS A MIXTURE WITH BLOOD AND OTHER FLUIDS DURING SPINAL SURGERY. CURRENTLY THERE ARE NO POC DIAGNOSTICS FOR CSF LEAKS AND EXISTING METHODS REQUIRE PATIENT SAMPLES TO BE SENT TO THIRD-PARTY LABORATORIES FOR RESULTS THAT CAN TAKE 4-7 DAYS. TREATMENT DELAYS OR MISDIAGNOSES SIGNIFICANTLY INCREASE THE RISK FOR LIFE-THREATENING MENINGITIS, INFECTIONS AND STROKE. PATIENTS WITH CSF RHINORRHEA THAT DEVELOP MENINGITIS HAVE ALSO HAVE MUCH HIGHER MORBIDITY RATES. ADDITIONALLY, THE WEEKLONG STAY NOT ONLY CAUSES SIGNIFICANT DISTRESS AND DISCOMFORT FOR THE PATIENT, BUT ALSO LEADS TO RADICALLY HIGHER HEALTHCARE COSTS. IN THIS DIRECT-TO-PHASE II PROPOSAL, CHEMELEON AIMS TO ADVANCE CSF LEAK DIAGNOSIS BY DEVELOPING A NOVEL, INEXPENSIVE BIOSENSOR THAT REQUIRES NO ADDITIONAL EQUIPMENT OR PERSONNEL TRAINING THAT CAN PROVIDE RESULTS IN MINUTES, ENABLING MEDICAL PROFESSIONALS TO MAKE TIME-SENSITIVE DECISIONS. CHEMELEON HAS ALREADY SUCCESSFULLY DEVELOPED A PROTOTYPE BINDING-INDUCED NANOSTRUCTURED DYNAMIC SURFACE (BINDS) ASSAY THAT BINDS THE CSF PROTEIN BIOMARKER, BETA-2-TRANSFERRIN (B2TR). THIS BINDS PLATFORM TECHNOLOGY INTEGRATES NANOPHOTONIC REPORTER SURFACES WITH B2TR-SPECIFIC APTAMER RECEPTORS, WHERE BINDING OF B2TR TO THE SENSOR SURFACE ALTERS THE SURFACE ENERGY PRODUCING A VIBRANT COLOR CHANGE THAT IS VISIBLE TO THE NAKED EYE. PROOF-OF- CONCEPT EXPERIMENTS REVEALED THAT CHEMELEON’S BINDS CSF ASSAY COULD DETECT 1 ΜG/ML OF B2TR IN 10 MINUTES, WHICH IS HIGHER THAN THE 4-5 ΜG/ML FOUND IN CSF. FOR DIRECT-TO-PHASE II STUDIES, THE CSF SENSOR WILL BE FURTHER DEVELOPED TO ACHIEVE THE HIGH SPECIFICITY, HIGH SENSITIVITY AND LOW READOUT TIME REQUIRED FOR USE IN CLINICAL AND FIELD SETTINGS. CHEMELEON WILL FOCUS ON (1) OPTIMIZING SENSOR PERFORMANCE TO RAPIDLY DISTINGUISH CSF FROM NASAL FLUID AND BLOOD SAMPLES, (2) FINALIZING MANUFACTURING PROCESSES FOR EFFICIENT SCALE-UP, AND (3) DESIGNING AND TESTING A COMMERCIAL IN VITRO DIAGNOSTIC PROTOTYPE. CHEMELEON’S CSF SENSOR WILL PROVIDE ADVANCEMENTS IN DECISION-MAKING FOR HEAD TRAUMA, SPINAL AND OTOLARYNGOLOGICAL SURGICAL CASES AND PRESENT A MODULAR PLATFORM FOR THE DEVELOPMENT OF OTHER HEALTHCARE DIAGNOSTICS.
Source: Federal Audit Clearinghouse (fac.gov)
Years audited
10
Clean years
10
Material Weakness
No
Noncompliance Issues
No
| Year | Status | Financial Report | Federal Expenditurecombined across all audits filed that year | Low Risk | Accepted |
|---|---|---|---|---|---|
| 2025 | Clean | Unmodified (Clean) | $13.3M | Yes | 2026-03-09 |
| 2024 | Clean | Unmodified (Clean) | $12.4M | Yes | 2025-03-13 |
| 2023 | Clean | Unmodified (Clean) | $12.5M | Yes | 2024-03-06 |
| 2022 | Clean | Unmodified (Clean) | $12.8M | Yes | 2023-02-27 |
| 2021 | Clean | Unmodified (Clean) | $9.5M | Yes | 2022-02-13 |
| 2020 | Clean | Unmodified (Clean) | $7.7M | Yes | 2021-02-09 |
| 2019 | Clean | Unmodified (Clean) | $8.5M | Yes | 2020-02-27 |
| 2018 | Clean | Unmodified (Clean) | $8.9M | Yes | 2019-03-10 |
| 2017 | Clean | Unmodified (Clean) | $8.3M | Yes | 2018-02-08 |
| 2016 | Clean | Unmodified (Clean) | $7.8M | Yes | 2017-02-20 |
Financial Report
Unmodified (Clean)
Federal Expenditure, combined across all audits filed that year
$13.3M
Financial Report
Unmodified (Clean)
Federal Expenditure, combined across all audits filed that year
$12.4M
Financial Report
Unmodified (Clean)
Federal Expenditure, combined across all audits filed that year
$12.5M
Financial Report
Unmodified (Clean)
Federal Expenditure, combined across all audits filed that year
$12.8M
Financial Report
Unmodified (Clean)
Federal Expenditure, combined across all audits filed that year
$9.5M
Financial Report
Unmodified (Clean)
Federal Expenditure, combined across all audits filed that year
$7.7M
Financial Report
Unmodified (Clean)
Federal Expenditure, combined across all audits filed that year
$8.5M
Financial Report
Unmodified (Clean)
Federal Expenditure, combined across all audits filed that year
$8.9M
Financial Report
Unmodified (Clean)
Federal Expenditure, combined across all audits filed that year
$8.3M
Financial Report
Unmodified (Clean)
Federal Expenditure, combined across all audits filed that year
$7.8M
Tax Year 2024 · Source: IRS e-Filed Form 990Schedule J available
Individuals serving as officers, directors, or trustees of the organization.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other |
|---|
Source: IRS Publication 78, Auto-Revocation List & e-Postcard Data
Tax-deductible contributions: Yes
Deductibility code: PC
Sources: IRS e-Filed Form 990 (XML) & ProPublica Nonprofit Explorer
Scroll →
| Year | Revenue | Contributions | Expenses | Assets | Net Assets |
|---|---|---|---|---|---|
| 2023IRS e-File | $16.9M | $16.7M | $13.9M | $24.2M | $16.8M |
| 2022IRS e-File | $15.1M | $15.9M | $13.9M | $16.7M | $13.8M |
| 2021 | $12.7M | $12.5M | $11.8M | $14.6M | $9.5M |
| 2020 | $12.2M |
Sources: ProPublica Nonprofit Explorer & IRS e-File Index
Financial data: IRS e-Filed Form 990 (Tax Year 2023)
Leadership & compensation: IRS e-Filed Form 990, Part VII (Tax Year 2024)
Federal grants: USAspending.gov (live)
Organization info: IRS Business Master File
Tax-deductibility: IRS Publication 78
| Total |
|---|
| Birgitta S Damon | Chief Executive Officer | 40 | $177.7K | $0 | $46.7K | $224.4K |
| Kara Murphy | Chief Financial Officer | 40 | $143.1K | $0 | $25.2K | $168.3K |
| James Low | President | 0.5 | $0 | $0 | $0 | $0 |
| Posan Ung | Vice President | 0.5 | $0 | $0 | $0 | $0 |
| Chris Bendicksen | Treasurer | 0.5 | $0 | $0 | $0 | $0 |
| Kimberly Rowe-Cummings | Clerk | 0.5 | $0 | $0 | $0 | $0 |
| Eddie Gomez | Asst Clerk | 0.5 | $0 | $0 | $0 | $0 |
| James Higgs | President | 0.5 | $0 | $0 | $0 | $0 |
Birgitta S Damon
Chief Executive Officer
$224.4K
Hrs/Wk
40
Compensation
$177.7K
Related Orgs
$0
Other
$46.7K
Kara Murphy
Chief Financial Officer
$168.3K
Hrs/Wk
40
Compensation
$143.1K
Related Orgs
$0
Other
$25.2K
James Low
President
$0
Hrs/Wk
0.5
Compensation
$0
Related Orgs
$0
Other
$0
Posan Ung
Vice President
$0
Hrs/Wk
0.5
Compensation
$0
Related Orgs
$0
Other
$0
Chris Bendicksen
Treasurer
$0
Hrs/Wk
0.5
Compensation
$0
Related Orgs
$0
Other
$0
Kimberly Rowe-Cummings
Clerk
$0
Hrs/Wk
0.5
Compensation
$0
Related Orgs
$0
Other
$0
Eddie Gomez
Asst Clerk
$0
Hrs/Wk
0.5
Compensation
$0
Related Orgs
$0
Other
$0
James Higgs
President
$0
Hrs/Wk
0.5
Compensation
$0
Related Orgs
$0
Other
$0
Highest compensated employees who are not officers or directors.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other | Total |
|---|---|---|---|---|---|---|
| Lilian Romero | Chief Program Officer | 40 | $130.1K | $0 | $31.8K | $161.9K |
| Jennifer L Mauche | Director Of Hr | 40 | $115.9K | $0 | $37.7K | $153.6K |
| Bridget G Bertrand | Program Director | 40 | $135.8K | $0 | $14K | $149.8K |
| Lisa Mcfadden | Development Director | 40 | $117.6K |
Lilian Romero
Chief Program Officer
$161.9K
Hrs/Wk
40
Compensation
$130.1K
Related Orgs
$0
Other
$31.8K
Jennifer L Mauche
Director Of Hr
$153.6K
Hrs/Wk
40
Compensation
$115.9K
Related Orgs
$0
Other
$37.7K
Bridget G Bertrand
Program Director
$149.8K
Hrs/Wk
40
Compensation
$135.8K
Related Orgs
$0
Other
$14K
Members of the governing board. Board members often serve without compensation.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other | Total |
|---|---|---|---|---|---|---|
| Adriana Moschella | Director | 0.5 | $0 | $0 | $0 | $0 |
| Diana Perez | Director | 0.5 | $0 | $0 | $0 | $0 |
| Jacqueline Gallo | Director | 0.5 | $0 | $0 | $0 | $0 |
| Jane Lavioe | Director | 0.5 | $0 | $0 | $0 | $0 |
| Joyce M Reen | Director | 0.5 | $0 | $0 | $0 | $0 |
| Nicole Mcclain | Director |
Adriana Moschella
Director
$0
Hrs/Wk
0.5
Compensation
$0
Related Orgs
$0
Other
$0
Diana Perez
Director
$0
Hrs/Wk
0.5
Compensation
$0
Related Orgs
$0
Other
$0
Jacqueline Gallo
Director
$0
Hrs/Wk
0.5
Compensation
$0
Related Orgs
$0
Other
$0
| $12M |
| $12M |
| $12.2M |
| $8.5M |
| 2019 | $12.2M | $11.9M | $10.9M | $10.8M | $8.3M |
| 2018 | $10.9M | $10.6M | $10.7M | $9.5M | $7M |
| 2017 | $10.4M | $10.2M | $10.1M | $9.8M | $6.9M |
| 2016 | $10.4M | $10.3M | $10M | $9.2M | $6.5M |
| 2015 | $10.5M | $10.2M | $10M | $9.1M | $5.4M |
| 2014 | $10.5M | $10.1M | $10.3M | $7.6M | $4M |
| 2013 | $10.9M | $10.5M | $10.8M | $6.9M | $3.7M |
| 2012 | $10.7M | $10.3M | $10.6M | $7M | $3.7M |
| 2011 | $12.6M | $686.3K | $10.9M | $7M | $3.9M |
| 2021 | 990 | Data |
| 2020 | 990 | Data | PDF not yet published by IRS |
| 2019 | 990 | Data |
| 2018 | 990 | Data |
| 2017 | 990 | Data |
| 2016 | 990 | Data |
| 2015 | 990 | Data |
| 2014 | 990 | Data |
| 2013 | 990 | Data |
| 2012 | 990 | Data |
| 2011 | 990 | Data |
| 2010 | 990 | — |
| 2009 | 990 | — |
| 2008 | 990 | — |
| 2007 | 990 | — |
| 2006 | 990 | — |
| 2005 | 990 | — |
| 2004 | 990 | — |
| 2003 | 990 | — |
| 2002 | 990 | — |
| 2001 | 990 | — |
| $0 |
| $23.4K |
| $141K |
| Marilyn Perry | Director Of Nutrition & Health | 40 | $117.7K | $0 | $17.7K | $135.3K |
Lisa Mcfadden
Development Director
$141K
Hrs/Wk
40
Compensation
$117.6K
Related Orgs
$0
Other
$23.4K
Marilyn Perry
Director Of Nutrition & Health
$135.3K
Hrs/Wk
40
Compensation
$117.7K
Related Orgs
$0
Other
$17.7K
| 0.5 |
| $0 |
| $0 |
| $0 |
| $0 |
| Paola Colunga | Director | 0.5 | $0 | $0 | $0 | $0 |
Jane Lavioe
Director
$0
Hrs/Wk
0.5
Compensation
$0
Related Orgs
$0
Other
$0
Joyce M Reen
Director
$0
Hrs/Wk
0.5
Compensation
$0
Related Orgs
$0
Other
$0
Nicole Mcclain
Director
$0
Hrs/Wk
0.5
Compensation
$0
Related Orgs
$0
Other
$0
Paola Colunga
Director
$0
Hrs/Wk
0.5
Compensation
$0
Related Orgs
$0
Other
$0